Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033306 · ClinicalTrials.gov registry record · Phase 2
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00033306 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 2 participants.
The verdict
NCT00033306, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic colorectal cancer.
Interventions
- DRUG Irinotecan
- DRUG ixabepilone
- DRUG Fluoropyrimidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2002-02 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033306
The ClinicalTrials.gov registry entry for NCT00033306 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Irinotecan is the first listed.
NCT00033306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033306 about?
NCT00033306 is a clinical study titled "BMS-247550 in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic colorectal cancer.
What is the current status of trial NCT00033306?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2002-02. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00033306?
The interventions under investigation include: Irinotecan (DRUG), ixabepilone (DRUG), Fluoropyrimidine (DRUG).
Who is sponsoring clinical trial NCT00033306?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.